Boston Scientific Launches AMS 700 LGX™ Inflatable Penile Prosthesis in China for Severe Erectile Dysfunction

NanjingAugust 28, 2022PR Newswire -- Today, at the Beijing Health Promotion Association's Male Health Focus Forum and the inauguration ceremony of the "Beijing Health Promotion Association Male Health Expert Committee," Boston Scientific (NYSE:BSX), a global leader in medical technology, officially announced the launch of its AMS 700 LGX™ penile implant in China for the treatment of severe male erectile dysfunction.

AMS 700 LGX™ continues the many advantages of its predecessor, such as excellent extensibility, prominent hardness, and effortless control, while achieving a technological breakthrough addressing the pain points of artificial corpora cavernosa implantation, allowing for an increase of up to 25% in both penile girth and length.^[1].[2].[3]Focusing on the needs of a large number of patients to improve their quality of life and enhance their health, the launch of AMS 700 LGX™ will provide doctors and patients with a higher-quality innovative solution.

Boston Scientific AMS 700 LGX Artificial Corpus Cavernosum Launch Event

"The Male Issue" Becomes Increasingly Severe, Relief of Pain Points Still Awaits Treatment Breakthrough

Erectile Dysfunction (ED) is one of the most common male sexual dysfunction diseases. Research data shows that the total prevalence rate among Chinese men over 40 years old is 40.2%.^[4]Erectile dysfunction is not only related to sexual health and family harmony, but also an early marker of cardiovascular disease, diabetes, depression and other diseases.^[5], and is therefore also known as the "indicator" of male physical and mental health.Seeking professional help and receiving standardized treatment as early as possible can help improve the quality of marital life and protect the patient's long-term health.。

Based on etiology, erectile dysfunction can be classified into psychogenic, organic, and mixed types. It is estimated that there are 8 to 10 million patients with organic erectile dysfunction in China.^[6]For patients with chronic or severe organic erectile dysfunction, conventional drug therapy, injection therapy, vacuum erection device therapy and other methods are difficult to fully meet their treatment needs.

Artificial corpora cavernosa implantation provides a flexible and effective treatment option for these patients with unmet needs, achieving normal erections by mechanically supporting the corpora cavernosa and "removing obstacles" from the root cause. This treatment method has been included as a first-line treatment option for erectile dysfunction by the American Urological Association.^[7]Patients who receive artificial corpora cavernosa implants generally report high satisfaction. However, postoperative issues such as the displacement of the prosthesis into deeper positions may lead to penile shortening, which has become a common complaint following the implantation of artificial corpora cavernosa.

Patented Material Aids Innovation Upgrade, Meeting Personalized Treatment Needs

Focusing on patients' pain points, Boston Scientific has introduced the patented product AMS 700 LGX™ from the AMS 700™ series into China. As an inflatable penile prosthesis, the AMS 700™ series features a "three-piece" design consisting of a concealed reservoir, cylinders, and a pump. It offers excellent width expansion, high rigidity when inflated, a natural flaccid state, and easy operation for effortless use, making sexual activity closer to a natural state. With over 40 years of clinical application, the series is sold in more than 50 countries worldwide and is highly trusted by surgeons and patients globally.

Boston Scientific AMS 700 LGX Artificial Corpora Cavernosa*

AMS 700 LGX™ not only continues the advantages of previous models but also achieves technological breakthroughs. Its cylinders adoptThe special polyester braided material patented can not only help patients restore penile length but also increase penile girth and length at most.25％^[1].[2].[3]The 12-month post-implantation follow-up data showed that, compared to the baseline, patients implanted with AMS 700 LGX™ had a median increase of 3 cm in length and 2 cm in girth.^[8]At the same time, AMS 700 LGX™ offers a variety of stacked rear-end extenders in different specifications for surgical selection, which can meet the personalized treatment needs of patients. It has a low mechanical failure rate, with no bending deformation or cylinder aneurysm occurrence.^[9], significantly improving patient satisfaction.

"Under the process of aging, the impact of erectile dysfunction on the quality of life of a large number of patients is becoming increasingly prominent. At the same time, the expectations of both doctors and patients for treatment options are also continuously increasing."Professor Yutian Dai, Chairman of the Male Health Expert Committee of Beijing Health Promotion Association, stated"The launch of AMS 700 LGX™ will further meet the diverse and personalized treatment needs of patients, and with the emergence of more innovative treatment methods, the level of andrology diagnosis and treatment in China will also see significant development."

Dabo, Vice President of Boston Scientific China's Peripheral and Oncology Intervention, Urology and Pelvic Health, and Device Services Division, stated:"Boston Scientific offers cutting-edge, comprehensive solutions in various niche fields such as men's health, stone management, and pelvic floor health, while continuously driving technological innovation to meet the evolving treatment needs of patients. The launch of AMS 700 LGX™ in China exemplifies our dedication and commitment. Moving forward, Boston Scientific will continue to leverage its strengths, using innovative power to address patients' 'unspoken concerns' and help improve the quality of life and health standards in China."

*Registration No.: Artificial Corpora Cavernosa and Accessories, China Medical Device Registration No. 20153134206

[1] Negro CL, Paradiso M, Rocca A, et al. Implantation of AMS 700 LGX penile prosthesis preserves penile length without the need for penile lengthening procedures. Asian J Androl. 2016 Jan-Feb;18(1):114-7.

[2] Christine B, Bella A. Controlled Expansion Cylinders: A Defined Post-Operative Inflation Protocol Yields Measurable Length Gain. Sexual Medicine Society of North America Meeting. Miami, Florida. Nov 2010. [poster80].

[3] Data on file with Boston Scientific.

[4] Zhang Qingjiang, Zhu Jichuan, Xu Qingquan, et al. Epidemiological Investigation of Erectile Function in 2226 Men from Three Cities[J]. Chinese Journal of Andrology, 2003, 17(3):3.

[5] Wu Tianmin, Hu Ping, Che Xiaoyan, et al. Investigation and Analysis of the Current Situation and Influencing Factors of Stigma in Male Patients with Erectile Dysfunction[J]. China Sexuality Science, 2021.

[6] Fang Jianwei, Chen Huixing, Ning Ye, et al. Analysis of Causes and Treatment Experience of Penile Prosthesis Reimplantation (A Report of 8 Cases) [J]. Chinese Journal of Andrology, 2010(10):4.

[7] Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh J, Khera M, McVary KT, Miner MM, Nelson CJ, Sadeghi-Nejad H, Seftel AD, Shindel AW. Erectile Dysfunction: AUA Guideline. J Urol. 2018 Sep;200(3):633-641. doi: 10.1016/j.juro.2018.05.004. Epub 2018 May 7. PMID: 29746858.

[8] Antonini G, De Berardinis E, Busetto GM, et al. Postoperative vacuum therapy following AMS™ LGX 700® inflatable penile prosthesis placement: penile dimension outcomes and overall satisfaction. Int J Impot Res. 2019 Feb 11. [Epub ahead of print]

[9] Kim KS, Bae WJ, Kim SW et al. Experience with AMS 700 LGX penile prostheses for preserving penile length in Korea. BMC Urol. 2019 Jan 16;19(1):6.

About Boston Scientific

Boston Scientific Corporation is committed to innovating for life. We are dedicated to pioneering medical solutions that improve the lives of patients around the world. For over four decades, Boston Scientific has consistently led the global medical technology industry by delivering a wide range of high-performance medical solutions that meet critical patient needs for treatment while reducing healthcare costs. For more detailed information, please visit the company’s website:www.bostonscientific.cn

About Boston Scientific Greater China

Boston Scientific established its China headquarters in Shanghai in 1997 and currently has branch offices in Beijing, Shanghai, Guangzhou, Chengdu, Hong Kong, and Taiwan. The company's core businesses encompass cardiac intervention, structural heart disease, cardiac rhythm management and electrophysiology, endoscopic intervention, peripheral and tumor intervention, urology and pelvic floor health, respiratory products, and more. Upholding its tradition as an innovation leader, Boston Scientific is committed to becoming a respected medical technology company that meets the needs of doctors and patients, demonstrates innovative vitality, and provides high-quality medical products and services for prevention, diagnosis, and treatment. For more detailed information, please visit the company website:www.bostonscientific.cn